Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504810 | 0.77 | CYP1A2 (0.48) | HTTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3505500 | 0.76 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6957700 | 0.74 | DRD3 (0.45) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6957894 | 0.73 | ADRA2C (0.41) | — | |
| SCHEMBL3505352 | 0.72 | LMNA (0.42) | MAPK1ALDH1A1HSD17B10GRM4 | |
| SCHEMBL3504376 | 0.71 | GRM4 (0.41) | ALDH1A1HSD17B10TSHRGRM4 | |
| SCHEMBL3510103 | 0.69 | HSP90AA1 (0.41) | ALDH1A1GRM4 | |
| SCHEMBL9386764 | 0.69 | LMNA (0.37) | ALDH1A1NTSR1GRM4 | |
| SCHEMBL3505067 | 0.66 | ACHE (0.40) | ALDH1A1HSD17B10GRM4 | |
| SCHEMBL12646517 | 0.65 | EDNRA (0.41) | HTTALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5494908-A | ANTIDEPRESSANT | HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) | 1996-02-27 | — | — | US | claimed |
| EP-0669920-B1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | AVENTIS PHARMA INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6046203-A | USEFUL FOR THE TREATMENT OF VARIOUS MEMORY DYSFUNCTIONS CHARACTERIZED BY A DECREASED CHOLINERGIC FUNCTION SUCH AS ALZHEIMER'S DISEASE; ALSO INHIBIT MONOAMINE OXIDASE AND HENCE ARE USEFUL AS ANTIDEPRESSANTS | AVENTIS PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5925766-A | COGNITION ACTIVATORS FOR DECREASING CHOLINERGIC FUNCTION OF ALZHEIMER*S DISEASE AND ARE ENZYME INHIBITORS OF MONOAMINE OXIDASE AND ARE ANTIDEPRESSANTS | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5756754-A | Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds | HOECHST MARION ROUSSEL, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5580982-A | ANTIDEPRESSANTS; ANTICHOLINERGIC AGENTS; ALZHEIMER'S DISEASE; AMINE OXIDASE INHIBITORS | HOECHST MARION ROUSSEL INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5494908-A | ANTIDEPRESSANT | HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0669920-A4 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS. | HOECHST ROUSSEL PHARMA (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669920-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST MARION ROUSSEL, Inc. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012495-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-06-09 | — | — | WO | disclosed |